399 related articles for article (PubMed ID: 33705563)
1. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort.
Bregenzer A; Bruggmann P; Castro E; Moriggia A; Rothen M; Thurnheer MC; Vernazza P; Scheidegger C
Swiss Med Wkly; 2021 Mar; 151():w20460. PubMed ID: 33705563
[TBL] [Abstract][Full Text] [Related]
2. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA
Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421
[TBL] [Abstract][Full Text] [Related]
3. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C prevalence and cascade of care among patients in the decentralised opioid agonist therapy programme of the canton of St Gallen, Switzerland: a cross-sectional study.
Wissel K; Vernazza P; Kuster S; Hensel-Koch K; Bregenzer A
Swiss Med Wkly; 2024 Feb; 154():3352. PubMed ID: 38579293
[TBL] [Abstract][Full Text] [Related]
5. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
7. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
8. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV
Clin Infect Dis; 2020 Sep; 71(6):1502-1510. PubMed ID: 31585005
[TBL] [Abstract][Full Text] [Related]
9. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
10. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
11. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
[TBL] [Abstract][Full Text] [Related]
12. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A
Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685
[TBL] [Abstract][Full Text] [Related]
13. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
[TBL] [Abstract][Full Text] [Related]
14. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study.
Sanvisens A; Rivas I; Faure E; Espinach N; Hernandez-Rubio A; Majó X; Colom J; Muga R
World J Gastroenterol; 2020 Oct; 26(38):5874-5883. PubMed ID: 33132641
[TBL] [Abstract][Full Text] [Related]
15. Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
Wolfson-Stofko B; Hirode G; Vanderhoff A; Karkada J; Capraru C; Biondi MJ; Hansen B; Shah H; Janssen HLA; Feld JJ
J Viral Hepat; 2024 May; 31(5):240-247. PubMed ID: 38385850
[TBL] [Abstract][Full Text] [Related]
16. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
18. Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
Chromy D; Bauer D; Simbrunner B; Jachs M; Hartl L; Schwabl P; Binter T; Steininger L; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Peck-Radosavljevic M; Mandorfer M; Reiberger T
Infect Dis (Lond); 2023 Mar; 55(3):189-198. PubMed ID: 36484317
[TBL] [Abstract][Full Text] [Related]
19. Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study).
Rolland B; Lions C; Di Beo V; Carrieri P; Authier N; Barré T; Delorme J; Mathurin P; Bailly F; Protopopescu C; Marcellin F
Harm Reduct J; 2022 Oct; 19(1):119. PubMed ID: 36303159
[TBL] [Abstract][Full Text] [Related]
20. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
